Eli Lilly and Company $LLY Shares Sold by AA Financial Advisors LLC

AA Financial Advisors LLC lowered its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 26.6% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,427 shares of the company's stock after selling 1,243 shares during the period. AA Financial Advisors LLC's holdings in Eli Lilly and Company were worth $2,671,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

• Eli Lilly’s Oral GLP-1 Breakthrough Could Change Everything

A number of other hedge funds also recently bought and sold shares of the stock. Diversified Trust Co raised its position in Eli Lilly and Company by 1.3% in the 2nd quarter. Diversified Trust Co now owns 16,834 shares of the company's stock valued at $13,123,000 after purchasing an additional 219 shares in the last quarter. Assenagon Asset Management S.A. raised its position in shares of Eli Lilly and Company by 106.8% during the 2nd quarter. Assenagon Asset Management S.A. now owns 1,481,031 shares of the company's stock worth $1,154,508,000 after acquiring an additional 765,010 shares in the last quarter. Perpetual Ltd raised its position in shares of Eli Lilly and Company by 7.1% during the 2nd quarter. Perpetual Ltd now owns 1,500 shares of the company's stock worth $1,169,000 after acquiring an additional 100 shares in the last quarter. International Private Wealth Advisors LLC raised its position in shares of Eli Lilly and Company by 40.1% during the 2nd quarter. International Private Wealth Advisors LLC now owns 1,676 shares of the company's stock worth $1,306,000 after acquiring an additional 480 shares in the last quarter. Finally, Livforsakringsbolaget Skandia Omsesidigt raised its position in shares of Eli Lilly and Company by 17.9% during the 2nd quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 27,706 shares of the company's stock worth $21,583,000 after acquiring an additional 4,200 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company's stock.

Eli Lilly and Company Trading Down 1.2%

Shares of LLY stock opened at $753.52 on Friday. The business's 50 day moving average is $738.37 and its two-hundred day moving average is $771.89. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $939.86. The company has a market capitalization of $713.18 billion, a P/E ratio of 49.25, a price-to-earnings-growth ratio of 1.06 and a beta of 0.47. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86.

• Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. During the same period last year, the business posted $3.92 EPS. The company's revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Equities analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, September 10th. Investors of record on Friday, August 15th were paid a $1.50 dividend. The ex-dividend date was Friday, August 15th. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.8%. Eli Lilly and Company's payout ratio is 39.22%.

Insider Transactions at Eli Lilly and Company

• As the Market Rotates, This Healthcare ETF Is Leading the Way

In other Eli Lilly and Company news, CEO David A. Ricks purchased 1,632 shares of the firm's stock in a transaction that occurred on Tuesday, August 12th. The shares were purchased at an average cost of $644.77 per share, for a total transaction of $1,052,264.64. Following the completion of the purchase, the chief executive officer directly owned 546,601 shares in the company, valued at $352,431,926.77. This represents a 0.30% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Gabrielle Sulzberger purchased 117 shares of the firm's stock in a transaction that occurred on Tuesday, August 12th. The stock was acquired at an average price of $641.18 per share, for a total transaction of $75,018.06. Following the completion of the purchase, the director owned 2,703 shares of the company's stock, valued at approximately $1,733,109.54. This represents a 4.52% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders bought 4,514 shares of company stock valued at $2,894,841. 0.13% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on LLY shares. JPMorgan Chase & Co. cut their target price on Eli Lilly and Company from $1,100.00 to $1,050.00 and set an "overweight" rating on the stock in a research report on Tuesday. Wall Street Zen downgraded Eli Lilly and Company from a "strong-buy" rating to a "buy" rating in a research note on Saturday. Berenberg Bank restated a "hold" rating and set a $830.00 price target (down previously from $970.00) on shares of Eli Lilly and Company in a research note on Wednesday. UBS Group dropped their price target on Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating on the stock in a research note on Friday, August 8th. Finally, Leerink Partnrs downgraded Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research note on Thursday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $939.61.

Get Our Latest Research Report on LLY

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Featured Stories

• Five stocks we like better than Eli Lilly and Company
• What Is WallStreetBets and What Stocks Are They Targeting?
• MarketBeat Week in Review – 09/15 - 09/19
• Using the MarketBeat Dividend Yield Calculator
• Tesla: 2 Reasons to Love Musk's $1B Buy, 1 Reason to Be Bearish
• What is MarketRank™? How to Use it
• Azure Leads While AI Excitement Fuels Microsoft Stock

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Eli Lilly and Company Right Now?

Before you consider Eli Lilly and Company, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.

While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here